Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Tubulin-interactive stilbene derivatives as anticancer agents.

Mikstacka R, Stefański T, Różański J.

Cell Mol Biol Lett. 2013 Sep;18(3):368-97. doi: 10.2478/s11658-013-0094-z. Epub 2013 Jul 1. Review.

PMID:
23818224
2.

Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.

Cushman M, Nagarathnam D, Gopal D, Chakraborti AK, Lin CM, Hamel E.

J Med Chem. 1991 Aug;34(8):2579-88.

PMID:
1875350
3.

Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4.

Marrelli M, Conforti F, Statti GA, Cachet X, Michel S, Tillequin F, Menichini F.

Curr Med Chem. 2011;18(20):3035-81. Review.

PMID:
21651481
4.

Interaction of 4-arylcoumarin analogues of combretastatins with microtubule network of HBL100 cells and binding to tubulin.

Rappl C, Barbier P, Bourgarel-Rey V, Grégoire C, Gilli R, Carre M, Combes S, Finet JP, Peyrot V.

Biochemistry. 2006 Aug 1;45(30):9210-8.

PMID:
16866367
5.

Stilbene derivatives that are colchicine-site microtubule inhibitors have antileukemic activity and minimal systemic toxicity.

Cao TM, Durrant D, Tripathi A, Liu J, Tsai S, Kellogg GE, Simoni D, Lee RM.

Am J Hematol. 2008 May;83(5):390-7. doi: 10.1002/ajh.21104.

6.

4,5-Diaryl-3-aminopyrazole derivatives as analogs of Combretastatin A-4: synthesis and biological evaluation.

Liu T, Cui R, Chen J, Zhang J, He Q, Yang B, Hu Y.

Arch Pharm (Weinheim). 2011 May;344(5):279-86. doi: 10.1002/ardp.201000069. Epub 2011 Feb 2.

PMID:
21290430
7.

Combretastatin A-4 analogues as antimitotic antitumor agents.

Nam NH.

Curr Med Chem. 2003 Sep;10(17):1697-722. Review.

PMID:
12871118
8.

The interaction with tubulin of a series of stilbenes based on combretastatin A-4.

Woods JA, Hadfield JA, Pettit GR, Fox BW, McGown AT.

Br J Cancer. 1995 Apr;71(4):705-11.

9.

Structure-based discovery of a boronic acid bioisostere of combretastatin A-4.

Kong Y, Grembecka J, Edler MC, Hamel E, Mooberry SL, Sabat M, Rieger J, Brown ML.

Chem Biol. 2005 Sep;12(9):1007-14.

10.

Developments of combretastatin A-4 derivatives as anticancer agents.

Shan Y, Zhang J, Liu Z, Wang M, Dong Y.

Curr Med Chem. 2011;18(4):523-38. Review.

PMID:
21143124
11.

Mechanism of action of antitumor drugs that interact with microtubules and tubulin.

Jordan MA.

Curr Med Chem Anticancer Agents. 2002 Jan;2(1):1-17. Review.

PMID:
12678749
12.

Quantum chemistry calculation-aided structural optimization of combretastatin A-4-like tubulin polymerization inhibitors: improved stability and biological activity.

Jiang J, Zheng C, Zhu K, Liu J, Sun N, Wang C, Jiang H, Zhu J, Luo C, Zhou Y.

J Med Chem. 2015 Mar 12;58(5):2538-46. doi: 10.1021/acs.jmedchem.5b00118. Epub 2015 Feb 26.

PMID:
25689111
13.

Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status.

Jaroch K, Karolak M, Górski P, Jaroch A, Krajewski A, Ilnicka A, Sloderbach A, Stefański T, Sobiak S.

Pharmacol Rep. 2016 Dec;68(6):1266-1275. doi: 10.1016/j.pharep.2016.08.007. Epub 2016 Aug 24. Review.

PMID:
27686966
14.

Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents.

Cushman M, Nagarathnam D, Gopal D, He HM, Lin CM, Hamel E.

J Med Chem. 1992 Jun 12;35(12):2293-306.

PMID:
1613753
15.

Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents.

Gwaltney SL 2nd, Imade HM, Barr KJ, Li Q, Gehrke L, Credo RB, Warner RB, Lee JY, Kovar P, Wang J, Nukkala MA, Zielinski NA, Frost D, Ng SC, Sham HL.

Bioorg Med Chem Lett. 2001 Apr 9;11(7):871-4.

PMID:
11294380
16.

Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a)

Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM, Hogan F.

J Med Chem. 1995 May 12;38(10):1666-72. Erratum in: J Med Chem 1995 Jul 21;38(15):2994.

PMID:
7752190
17.

A concise synthesis of pyrazole analogues of combretastatin A1 as potent anti-tubulin agents.

Zaninetti R, Cortese SV, Aprile S, Massarotti A, Canonico PL, Sorba G, Grosa G, Genazzani AA, Pirali T.

ChemMedChem. 2013 Apr;8(4):633-43. doi: 10.1002/cmdc.201200561. Epub 2013 Feb 21.

PMID:
23436706
18.

Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects.

Barrett I, Carr M, O'Boyle N, Greene LM, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ.

J Enzyme Inhib Med Chem. 2010 Apr;25(2):180-94. doi: 10.3109/14756360903169659.

PMID:
20222762
19.

Comparative molecular field analysis study of stilbene derivatives active against A549 lung carcinoma.

Kim S, Min SY, Lee SK, Cho WJ.

Chem Pharm Bull (Tokyo). 2003 May;51(5):516-21.

20.

The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.

Greene LM, Nathwani SM, Bright SA, Fayne D, Croke A, Gagliardi M, McElligott AM, O'Connor L, Carr M, Keely NO, O'Boyle NM, Carroll P, Sarkadi B, Conneally E, Lloyd DG, Lawler M, Meegan MJ, Zisterer DM.

J Pharmacol Exp Ther. 2010 Nov;335(2):302-13. doi: 10.1124/jpet.110.170415. Epub 2010 Aug 10.

Supplemental Content

Support Center